Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Cantor Fitzgerald Positive on Lucid Diagnostics Inc (LUCD) Following Earnings
August 13, 2024 2:57 PM EDTCantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).
The analyst comments "We reiterate our Overweight rating and 12-month price target of $3.00 on Lucid Diagnostics' (LUCD) shares following the company reporting 2Q24 operating results and providing... More
Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
August 12, 2024 4:47 PM EDTNeedham analyst Mike Matson reiterated a Buy rating and $2.50 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).
The analyst comments "In 2Q24, EsoGuard test volume grew 30% sequentially and 43% Y/Y to 3,147. LUCD missed consensus revenue in 2Q24 and we note that LUCD has... More
